Prestige Consumer Healthcare Inc. PBH
We take great care to ensure that the data presented and summarized in this overview for Prestige Consumer Healthcare Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PBH
View all-
Black Rock Inc. New York, NY8.28MShares$674 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.68MShares$463 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.96MShares$241 Million0.05% of portfolio
-
Ariel Investments, LLC Chicago, IL2.78MShares$227 Million2.25% of portfolio
-
Macquarie Group LTD Australia, C32.67MShares$218 Million0.21% of portfolio
-
Victory Capital Management Inc2.07MShares$169 Million0.15% of portfolio
-
State Street Corp Boston, MA2.01MShares$163 Million0.01% of portfolio
-
Allspring Global Investments Holdings, LLC1.58MShares$128 Million0.18% of portfolio
-
Geode Capital Management, LLC Boston, MA1.33MShares$108 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.12MShares$91.3 Million0.01% of portfolio
Latest Institutional Activity in PBH
Top Purchases
Top Sells
About PBH
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Insider Transactions at PBH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 18
2024
|
Ronald M. Lombardi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
82,237
-11.32%
|
$6,743,434
$82.54 P/Share
|
Nov 18
2024
|
Ronald M. Lombardi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
82,237
+10.14%
|
$4,605,272
$56.65 P/Share
|
Nov 12
2024
|
Mary Beth Fritz SVP Quality & Regulatory |
SELL
Open market or private sale
|
Direct |
9,885
-20.46%
|
$800,685
$81.96 P/Share
|
Nov 12
2024
|
Mary Beth Fritz SVP Quality & Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
9,885
+16.83%
|
$464,595
$47.23 P/Share
|
Nov 12
2024
|
Adel Mekhail EVP, Marketing & Sales |
SELL
Open market or private sale
|
Direct |
9,063
-33.04%
|
$743,166
$82.0 P/Share
|
Nov 12
2024
|
Adel Mekhail EVP, Marketing & Sales |
BUY
Exercise of conversion of derivative security
|
Direct |
5,565
+16.87%
|
$244,860
$44.33 P/Share
|
Nov 12
2024
|
Christine Sacco Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
24,686
-45.04%
|
$2,024,252
$82.01 P/Share
|
Nov 12
2024
|
Christine Sacco Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,686
+31.05%
|
$740,580
$30.56 P/Share
|
Nov 12
2024
|
William P'Pool Officer |
SELL
Open market or private sale
|
Direct |
8,987
-30.94%
|
$727,947
$81.85 P/Share
|
Aug 06
2024
|
James D Arecca Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,202
+32.87%
|
-
|
Aug 06
2024
|
Sheila Hopkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,202
+7.28%
|
-
|
Aug 06
2024
|
Dawn M. Zier Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,202
+13.23%
|
-
|
Aug 06
2024
|
John F. Kelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,202
+44.4%
|
-
|
Aug 06
2024
|
John E Byom Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,202
+4.03%
|
-
|
Aug 06
2024
|
Celeste A. Clark Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,202
+16.15%
|
-
|
Aug 05
2024
|
John F. Kelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
555
+50.0%
|
-
|
May 07
2024
|
Ronald M. Lombardi Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,298
+4.26%
|
-
|
May 07
2024
|
Mary Beth Fritz SVP Quality & Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
2,042
+9.78%
|
-
|
May 07
2024
|
William P'Pool Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,123
+9.71%
|
-
|
May 07
2024
|
Christine Sacco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,062
+16.75%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 169K shares |
---|---|
Exercise of conversion of derivative security | 195K shares |
Payment of exercise price or tax liability | 73.9K shares |
---|---|
Open market or private sale | 222K shares |